ADMA Biologics Inc (ADMA)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Adam S. Grossman
Employees:
530
C/O ADMA BIOLOGICS, INC., 465 STATE ROUTE 17, RAMSEY, NJ 07446
(201) 478-5552

ADMA Biologics, Inc. engages in developing, manufacturing, and marketing specialty plasma-derived biologics. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI) and ASCENIV. Nabi-HB for the. treatment of acute exposure to blood containing Hepatitis B surface antigen.

Data derived from most recent annual or quarterly report
Market Cap 636.74 Million Shares Outstanding195.92 Million Avg 30-day Volume 3.295 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.15
Price to Revenue3.6573 Debt to Equity1.5142 EBITDA-37.876 Million
Price to Book Value4.7538 Operating Margin-35.635600000000004 Enterprise Value594.309 Million
Current Ratio5.043 EPS Growth0.453 Quick Ratio1.256
1 Yr BETA 1.256 52-week High/Low 3.47 / 1.17 Profit Margin-53.8942
Operating Cash Flow Growth22.9736 Altman Z-Score-0.1021 Free Cash Flow to Firm -87.296 Million
View SEC Filings from ADMA instead.

View recent insider trading info

Funds Holding ADMA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ADMA

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-31:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-27:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-21:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-13:
    Item 8.01: Other Events
  • 8-K: filed on 2022-05-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-25:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-24:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-09:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    LENZ BRIAN EVP, CFO

    1,027,832 2022-09-30 4

    GROSSMAN ADAM S PRESIDENT AND CEO

    3,898,126 2022-09-30 4

    DEMSKI MARTHA J

    83,958 2022-03-07 1

    ELMS STEVE

    3,695,429 2022-03-07 1

    FONG BRYANT

    1,520,562 2022-03-07 1

    GROSSMAN JERROLD B

    433,329 2022-03-07 1

    GUIHEEN LAWRENCE P.

    158,258 2022-03-07 1

    KWON YOUNG

    279,758 2022-03-07 1

    PERCEPTIVE ADVISORS LLC

    PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

    EDELMAN JOSEPH

    • 10% Owner
    13,262,375 2021-09-28 0

    MOND JAMES EVP, CSO AND CMO

    • Officer
    276,535 2021-02-25 0

    GOLDSTEIN DOV A MD

    • Director
    7,500 2020-02-28 0

    RICHMAN ERIC I

    • Director
    44,030 2020-02-28 0

    BIOTEST DIVESTITURE TRUST

    • 10% Owner
    4,295,580 2019-06-06 0

    BIOTEST AG

    BIOTEST PHARMACEUTICALS CORP

    • 10% Owner
    10,109,534 2018-05-14 0

    EHMER BERNHARD

    • Director
    0 2017-06-06 0

    AISLING CAPITAL II LP

    AISLING CAPITAL PARTNERS LLC

    AISLING CAPITAL PARTNERS, LP

    SCHIFF ANDREW N

    PURCELL DENNIS J

    ELMS STEVE

    • 10% Owner
    3,620,143 2013-10-22 0

    WARSHAW KIRK M CFO, SECRETARY

    • Officer
    100,000 2006-09-08 0

    R & R INVESTMENTS VI LLC

    • 10% Owner
    2,000,000 2006-09-08 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    LENZ BRIAN EVP, CFO

    2022-10-04 21:01:58 -0400 2022-09-30 F 73,678 $2.43 d 1,027,832 direct -2.963 -5.9259 17.037 22.5926 29 -8.5185 26

    GROSSMAN ADAM S PRESIDENT AND CEO

    2022-10-04 21:21:56 -0400 2022-09-30 F 101,315 $2.43 d 2,188,725 direct -2.963 -5.9259 17.037 22.5926 29 -8.5185 26

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ADMA BIOLOGICS INC ADMA 2022-11-25 22:15:03 UTC 2.5289 1.2911 2600000
    ADMA BIOLOGICS INC ADMA 2022-11-25 21:45:04 UTC 2.5289 1.2911 2600000
    ADMA BIOLOGICS INC ADMA 2022-11-25 21:15:03 UTC 2.5289 1.2911 2600000
    ADMA BIOLOGICS INC ADMA 2022-11-25 20:45:03 UTC 2.5289 1.2911 2600000
    ADMA BIOLOGICS INC ADMA 2022-11-25 20:15:03 UTC 2.5289 1.2911 2600000
    ADMA BIOLOGICS INC ADMA 2022-11-25 19:45:04 UTC 2.5289 1.2911 2600000
    ADMA BIOLOGICS INC ADMA 2022-11-25 19:15:03 UTC 2.5289 1.2911 2600000
    ADMA BIOLOGICS INC ADMA 2022-11-25 18:45:03 UTC 2.5289 1.2911 2600000
    ADMA BIOLOGICS INC ADMA 2022-11-25 18:15:03 UTC 2.5289 1.2911 2600000
    ADMA BIOLOGICS INC ADMA 2022-11-25 17:45:04 UTC 2.5289 1.2911 2600000
    ADMA BIOLOGICS INC ADMA 2022-11-25 17:15:03 UTC 2.5289 1.2911 2600000
    ADMA BIOLOGICS INC ADMA 2022-11-25 16:45:04 UTC 2.5289 1.2911 2600000
    ADMA BIOLOGICS INC ADMA 2022-11-25 16:15:03 UTC 2.5289 1.2911 2600000
    ADMA BIOLOGICS INC ADMA 2022-11-25 15:45:03 UTC 2.5289 1.2911 2600000
    ADMA BIOLOGICS INC ADMA 2022-11-25 15:15:03 UTC 2.5289 1.2911 2600000
    ADMA BIOLOGICS INC ADMA 2022-11-25 14:45:04 UTC 2.5289 1.2911 2600000
    ADMA BIOLOGICS INC ADMA 2022-11-25 14:15:04 UTC 2.5289 1.2911 2600000
    ADMA BIOLOGICS INC ADMA 2022-11-25 13:45:03 UTC 3.4017 0.4183 2600000
    ADMA BIOLOGICS INC ADMA 2022-11-25 13:15:03 UTC 3.4017 0.4183 2600000
    ADMA BIOLOGICS INC ADMA 2022-11-25 12:45:03 UTC 3.4017 0.4183 2600000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund ADMA -11700.0 shares, $-28431.0 2022-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments